Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF
13 May 2024 (08:54 - 09:02)
Organised by: 
Slides
About the speaker
St. Luke's Mid America Heart Institute, Kansas City (United States of America)
9 More presentations in this session
Professor S. von Haehling (Goettingen, DE)
Professor M. Petrie (Glasgow, GB)
Access the full session
The Event
Heart Failure 2024
13 May 2024
08:54 CET
